Findings showed atezolizumab in combination with paclitaxel did not meet statistical significance for progression free survival and also demonstrated a negative trend in overall survival.
Detectnet (copper Cu 64 dotatate) is indicated for use with PET for localization of somatostatin receptor positive neuroendocrine tumors.
The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.
Five antihypertensive drug classes were analyzed separately and were also compared to all other treatment groups, including placebo.
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.
This slideshow shows drug information for Blenrep. Click here for the complete Blenrep monograph.
The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.
Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.
The Food and Drug Administration (FDA) has granted Priority Review to tepotinib (EMD Serono) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 (METex14) skipping, as detected by an FDA-approved test. The application is supported by data from the ongoing,…
The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.
